Cost-utility analysis of Palbociclib + letrozole and ribociclib + letrozole versus Letrozole monotherapy in the first-line treatment of metastatic breast cancer in Iran using partitioned survival model

BACKGROUND: Palbociclib and Ribociclib are cyclin-dependent kinase 4/6 oral molecular inhibitors that have the potential to improve overall survival (OS), progression-free survival (PFS), and quality of life in patients with metastatic breast cancer (MBC). The objective of this study was to analyze...

Descripción completa

Detalles Bibliográficos
Autores principales: Darvishi, Ali, Daroudi, Rajabali, Fazaeli, Ali Akbar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10633960/
https://www.ncbi.nlm.nih.gov/pubmed/37943359
http://dx.doi.org/10.1186/s13561-023-00463-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10633960/
https://www.ncbi.nlm.nih.gov/pubmed/37943359
http://dx.doi.org/10.1186/s13561-023-00463-6

Ejemplares similares